About Evolus®
Meet Jeuveau
EXCLUSIVE OFFER
Glidewell customers qualify for special pricing! Fill out the form at the bottom to learn more.
Results that Speak Volumes.
The Power of Precision
- A precise, tight field of effect that puts control in your hands1*
- Natural looking results, exactly where you want them6,7
- Consistent outcomes, for consistently satisfied patients6,7
Proven Results
- 2 Phase III pivotal studies (n=654)7
- The largest head-to-head aesthetics EU/Canada Phase Ill trial vs. Botox® Cosmetic (n=540)5
- 2 long-term safety studies (n=922)8,9*
In 2 US pivotal Phase Ill studies, 68% and 70% of Jeuveau patients with moderate to severe frown lines had a 2-grade or better physician- and patient-rated improvement (none or mild frown lines) at Day 30, compared to 1% for placebo.
Faceoff Against Botox® Cosmetic
- 82.8% of Botox® Cosmetic patients saw significant improvement vs 87.2% of Jeuveau patients at Day 305
- 26/30 exploratory endpoints numerically favored Jeuveau vs. Botox® Cosmetic5
Patient Satisfaction
*Based on the 5-point Global Aesthetic Improvement Scale (GAIS) (exploratory endpoint).
†Consumer Pulse Survey of 424 Jeuveau users who were treated within the last 3 months and have received 5 or more treatments. Question: Please rate your overall satisfaction with Jeuveau® neurotoxin treatment. Results based on ratings of 4 and 5 on a 5-point scale, where 1= “Not at all satisfied” and 5=”Extremely satisfied”.
JEUVEAU® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of JEUVEAU®:
- Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
- Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing.
Do not use JEUVEAU® if you: are allergic to any of the ingredients in JEUVEAU® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®/BOTOX® Cosmetic), abobotulinumtoxinA (DYSPORT®), or incobotulinumtoxinA (XEOMIN®); have a skin infection at the planned injection site; or are a child.
JEUVEAU dosing units are not the same as, or comparable to, any other botulinum toxin product.
Tell your healthcare provider about all your muscle or nerve conditions, such as ALS or Lou Gehrig’s disease, Myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of JEUVEAU®.
Tell your healthcare provider about all your medical conditions, including: any side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles; drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed (it is not known if JEUVEAU® can harm your unborn baby or passes into breast milk).
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using JEUVEAU® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received JEUVEAU® in the past.
Especially tell your healthcare provider if you: have received any other botulinum toxin product in the past and the last 4 months, and exactly which product you received (such as BOTOX, BOTOX Cosmetic, MYOBLOC, DYSPORT, or XEOMIN).
JEUVEAU® may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of treatment with JEUVEAU®. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
JEUVEAU® can cause other serious side effects including: Allergic reactions such as itching, rash, red itchy welts, wheezing, trouble breathing, asthma symptoms, or dizziness or feeling faint. Tell your healthcare provider or get emergency medical help right away if you develop wheezing or trouble breathing, or if you feel dizzy or faint. Heart problems. Irregular heartbeat and heart attack that have caused death, have happened in some people who received botulinum toxin products. Eye problems such as dry eye, reduced blinking, and corneal problems. Tell your healthcare provider if you develop eye pain or irritation, sensitivity to light, or changes in your vision.
The most common side effects include: headache; eyelid drooping, upper respiratory tract infection, and increased white blood cell count.
JEUVEAU® is a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).
The risk information provided here is not complete. For more information about JEUVEAU, see the full Prescribing Information including BOXED WARNING, and Medication Guide, or talk to your healthcare provider.
To report side effects associated with use of JEUVEAU, please call 1-877-EVOLUS1/1-877-386-5871. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Exclusively licensed and manufactured for: Evolus, Inc., 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660
©2024 Evolus, Inc. All rights reserved. All trademarks are the property of their respective owners
To place an order for Jeuveau, please fill out the form below.
- Kaminer MS, Cox SE, Fagien S, Kaufman J, Lupo M, Shamban A. Re-examining the optimal use of neuromodulators and the changing landscape: A consensus panel update. J Drugs Dermatol. 2020;19(4 suppl 1):s5-15.
- Rzany B. A multicenter , randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J. 2020;40(4):413-429.
- Jeuveau Experience Treatment (J.E.T.) Interim Data Report, 12/16/2019; Evolus, Inc.
- Beer K. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phrase III studies. Dermatol Surg. 2019;45(11):1381-1393.
- Data on file; CSR EV-001, BLA761085. Evolus, Inc., Newport Beach, CA.
- Data on file; CSR EV-002, BLA761085. Evolus, Inc., Newport Beach, CA.
- Data on file; CSR EV-003, BLA761085. Data on file; CSR EV-001, BLA761085. Evolus, Inc., Newport Beach, CA.
- Data on file; CSR EV-004, BLA761085. Evolus, Inc., Newport Beach, CA.
- Data on file; CSR EV-006, BLA761085. Evolus, Inc., Newport Beach, CA.
- Data on file; REF-00258, Evolus, Inc., Newport Beach, CA.
